Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi-1 leukemia cells

Molecular Medicine Reports

Volumn 9, Issue 2, 2014, Pages 443-449

  Zhang, Zhi Hua ^a   Hao, Chang Lai ^a   Liu, Peng ^b   Tian, Xia ^c   Wang, Li Hong ^a   Zhao, Lei ^a   Zhu, Cui Min ^a  

^a CHENGDE MEDICAL COLLEGE   (China)

^b FIRST HOSPITAL OF SHIJIAZHUANG   (China)

^c 89 Hospital of PLA   (China)

Author keywords

Histone deacetylase; Kasumi 1 cells; Tumor angiogenesis; Valproic acid

Indexed keywords

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VALPROIC ACID; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893846614     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1834     Document Type: Article

References (29)

1. Wichmann C, Chen L, Heinrich M, et al: Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells. Cancer Res 67: 2280-2289, 2007.
2. Minucci S, Nervi C, Lo Coco F and Pelicci PG: Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20: 3110-3115, 2001.
3. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG and Lazar MA: Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18: 7185-7191, 1998.
4. Hug BA and Lazar MA: ETO interacting proteins. Oncogene 23: 4270-4274, 2004.
5. Le XF, Claxton D, Kornblau S, Fan YH, Mu ZM and Chang KS: Characterization of the ETO and AML1-ETO proteins involved in 8;21 translocation in acute myelogenous leukemia. Eur J Haematol 60: 217-225, 1998.
6. Lutterbach B, Westendorf JJ, Linggi B, et al: ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 18: 7176-7184, 1998.
7. Marks PA, Richon VM and Rifkind RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216, 2000.
8. Redner RL, Wang J and Liu JM: Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 94: 417-428, 1999.
9. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT and De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56: 549-580, 2004.
10. Nussenbaum F and Herman IM: Tumor angiogenesis: insights and innovations. J Oncol 2010: 132641, 2010.
11. Sasakawa Y, Naoe Y, Noto T, et al: Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol 66: 897-906, 2003.
12. Göttlicher M, Minucci S, Zhu P, et al: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978, 2001.
13. Zhao L, Zhang ZH and Zhu CM: Inhibitory effect of valproic acid on cell cycle of Kasumi-1 cell line and its mechanism. Zhonghua Xue Ye Xue Za Zhi 29: 802-805, 2008 (In Chinese).
14. Zhu CM, Zhang ZH, Jiang FY, et al: Effects of histone deacetylase inhibitor on the expression of angiogenesis related factors in Kasumi-1 leukemic cell line. Zhonghua Xue Ye Xue Za Zhi 31: 466-469, 2010 (In Chinese).
15. Poon RT, Ng IO, Lau C, et al: Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 20: 1775-1785, 2002.
16. Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147: 9-19, 1995.
17. Larizza L, Magnani I and Beghini A: The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma 46: 247-255, 2005.
18. Liu S, Klisovic RB, Vukosavljevic T, et al: Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J Pharmacol Exp Ther 321: 953-960, 2007.
19. Hiramatsu A, Miwa H, Shikami M, et al: Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML. Leuk Lymphoma 47: 89-95, 2006.
20. Imai N, Shikami M, Miwa H, et al: t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt. Br J Haematol 135: 673-682, 2006.
21. Mühlethaler-Mottet A, Meier R, Flahaut M, et al: Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mol Cancer 7: 55, 2008.
22. Yang QC, Zeng BF, Shi ZM, et al: Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma. J Exp Clin Cancer Res 25: 593-599, 2006.
23. Mie Lee Y, Kim SH, Kim HS, et al: Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun 300: 241-246, 2003.
24. Williams RJ: Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis. Expert Opin Investig Drugs 10: 1571-1573, 2001.
25. Kim MS, Kwon HJ, Lee YM, et al: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7: 437-443, 2001.
26. Tovar-Castillo LE, Cancino-Díaz JC, García-Vázquez F, et al: Under-expression of VHL and over-expression of HDAC-1, HIF-1alpha, LL-37, and IAP-2 in affected skin biopsies of patients with psoriasis. Int J Dermatol 46: 239-246, 2007.
27. Ellis L, Hammers H and Pili R: Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 280: 145-153, 2009.
28. Strahl BD and Allis CD: The language of covalent histone modifications. Nature 403: 41-45, 2000.
29. Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 389: 349-352, 1997.